Top

BY Clayton Boldt, Ph.D.

In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy viewed under the microscope. However, it’s well-established that if no further treatment is given, some patients will relapse due to undetectable cancer cells remaining in the body. This small number of remaining cells is known as minimal residual disease (MRD).

Ghayas Issa, M.D., assistant...

Ghayas Issa, M.D.

BY Clayton Boldt, Ph.D.

Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have...

BY Clayton Boldt, Ph.D.

Chimeric antigen receptor (CAR) T cells were approved by the Food and Drug Administration (FDA) to treat relapsed and refractory large B-cell...

BY Clayton R. Boldt, Ph.D.

Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important role in advancing these novel treatments to the clinic. With recent agreements, MD Anderson has expanded its manufacturing and research capacity for cell therapies to bring new treatment options to more patients.

This month, MD Anderson finalized an asset purchase agreement with Bellicum...

Jason Bock, Ph.D., Vice President, Therapeutics Discovery

BY Clayton Boldt, Ph.D.

MD Anderson has created a new research platform to drive the discovery of new therapeutic agents for patients with leukemia by investigating...

BY Jill Russell, Ph.D.

Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...

BY Clayton Boldt, Ph.D.

MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...

BY Clayton Boldt, Ph.D.

Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...

BY Clayton Boldt, Ph.D.

Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...

BY Clayton Boldt, Ph.D.

Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...